| __timestamp | ADMA Biologics, Inc. | Alnylam Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 44526000 |
| Thursday, January 1, 2015 | 6745968 | 60610000 |
| Friday, January 1, 2016 | 8494742 | 89354000 |
| Sunday, January 1, 2017 | 18092835 | 199365000 |
| Monday, January 1, 2018 | 22502922 | 382359000 |
| Tuesday, January 1, 2019 | 25910757 | 479005000 |
| Wednesday, January 1, 2020 | 35050817 | 588420000 |
| Friday, January 1, 2021 | 42896889 | 620639000 |
| Saturday, January 1, 2022 | 52458024 | 770658000 |
| Sunday, January 1, 2023 | 59020000 | 795646000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Alnylam Pharmaceuticals, Inc. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, Alnylam Pharmaceuticals has consistently outpaced ADMA Biologics in SG&A spending, reflecting its aggressive growth strategy. By 2023, Alnylam's SG&A expenses surged by approximately 1,700% from 2014, reaching nearly $796 million. In contrast, ADMA Biologics saw a more modest increase of around 1,100%, with expenses rising to about $59 million. This disparity highlights Alnylam's expansive operational scale and market penetration efforts. Investors and industry analysts can glean insights into each company's strategic priorities and operational efficiencies through these financial metrics. As the biotech sector evolves, monitoring such trends will be pivotal in assessing corporate health and future potential.
Eli Lilly and Company vs ADMA Biologics, Inc.: SG&A Expense Trends
Regeneron Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Alnylam Pharmaceuticals, Inc. or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? United Therapeutics Corporation or ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and PTC Therapeutics, Inc.
ADMA Biologics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
ADMA Biologics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and MiMedx Group, Inc.